Tranylcypromine

MAOI interaction may manifest as serotonin syndrome or opioid toxicity including respiratory depression and coma. Use not recommended or within 14 days of stopping.

Nonselective MAO inhibitor use with carbidopa and levodopa is contraindicated. Discontinue at least two weeks prior to initiating therapy.

Concomitant use increases risk of serotonin syndrome. Contraindicated with MAOI or within 14 days of stopping MAOI.

Concomitant use increases risk of serotonin syndrome. Contraindicated with MAOIs intended to treat psychiatric disorders or within 14 days of stopping MAOI.

Concomitant use increases risk of serotonin syndrome. Contraindicated with MAOI intended to treat psychiatric disorders or within 7 days of stopping desvenlafaxine.

Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure.

MAOI that potentiates amphetamine effects; concomitant use can cause hypertensive crisis with potentially fatal outcomes including stroke, MI, aortic dissection.

MAOI concomitant use can cause hypertensive crisis with potentially fatal outcomes including stroke, myocardial infarction, and aortic dissection. Do not use concurrently or within 14 days after discontinuing.

Concomitant use increases risk of serotonin syndrome. Use of tranylcypromine with duloxetine or within 5 days of stopping duloxetine is contraindicated.

Direct-acting sympathomimetic contraindicated; emergency use only with close monitoring and immediate discontinuation of tranylcypromine if necessary.

Contraindicated due to risk of clinically significant adverse reactions. Minimum 5-week washout period required before starting tranylcypromine due to fluoxetine's long half-life.

Nonselective MAO inhibitor use with VYALEV is contraindicated. Discontinue at least two weeks prior to initiating VYALEV.

Not recommended for patients taking MAOIs or within 14 days of stopping. May manifest as serotonin syndrome or opioid toxicity.

MAOI that increases risk of serotonin syndrome when used with levomilnacipran. Contraindicated use.

Contraindicated; emergency use only with close monitoring and immediate discontinuation of tranylcypromine if necessary.

Meperidine is contraindicated in patients receiving MAOIs. Can cause unpredictable, severe, and occasionally fatal reactions including coma, respiratory depression, serotonin syndrome, convulsions, and hypertension.

Intravenous methylene blue is contraindicated; emergency use only with close monitoring and immediate discontinuation of tranylcypromine if necessary.

Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, and other serious complications.

Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, aortic dissection, and renal failure.

Product Clinical Comment on Concomitant Use [See Contraindications (4.1)] ; Predominant Effect/Risk [Hypertensive Reaction (HR) [See Warnings and Precautions (5.3)] ; or Serotonin Syndrome (SS) [See Warnings and Precautions (5.7)] ] Altretamine Use with caution If not otherwise specified in this table, consider avoiding concomitant use (see also information on medication-free intervals , use agent at the lowest appropriate dose, monitor for effects of the interaction, advise the patient to report potential effects, and be prepared to discontinue the agent and treat effects of the interaction Orthostatic hypotension [See Warnings and Precautions (5.5)] Buspirone Contraindicated HR Carbamazepine Contraindicated SS Chlorpromazine Use with caution Hypotensive effects Cyclobenzaprine Contraindicated SS Dextromethorphan Contraindicated SS; Psychosis, bizarre behavior Dopamine Contraindicated HR Droperidol Use with caution QT interval prolongation Entacapone Use with caution HR Fentanyl Use with caution SS Hydroxytryptophan Contraindicated SS Levodopa Contraindicated HR Lithium Use with caution SS Meperidine Contraindicated SS Methadone Use with caution SS Methyldopa Contraindicated HR Metoclopramide Use with caution HR/SS Mirtazapine Contraindicated SS Oxcarbazepine Use with caution because of close structural relationship with tricyclic antidepressants SS Rasagiline Contraindicated HR Reserpine Contraindicated HR S-adenosyl-L-methionine (SAM-e) Contraindicated SS Tapentadol Contraindicated HR/SS Tetrabenazine Contraindicated HR Tolcapone Use with caution HR Tramadol Use with caution SS; Increased seizure risk Tryptophan Contraindicated SS 7.2 Tyramine-Containing Foods and Beverages Tranylcypromine tablets inhibits intestinal MAO, which is responsible for the catabolism of tyramine in food and beverages.

Concomitant use increases risk of serotonin syndrome. Mirtazapine is contraindicated in patients taking MAOIs.

Do not use morphine in patients taking MAOIs or within 14 days of stopping treatment; may cause serotonin syndrome or opioid toxicity.

Use not recommended for patients taking MAOIs or within 14 days of stopping. Can cause serotonin syndrome or opioid toxicity including respiratory depression and coma.

Non-selective MAO inhibitor that inhibits catecholamine metabolism. Concomitant use may increase risk of arrhythmias, increased heart rate, and excessive blood pressure changes.

MAOI that increases risk of serotonin syndrome when combined with paroxetine. Paroxetine is contraindicated.

Concomitant use of SSRIs including paroxetine and MAOIs increases the risk of serotonin syndrome.

Concomitant use increases risk of serotonin syndrome.

Nonselective MAO inhibitor contraindicated with rizatriptan due to increased plasma concentrations and potential for serious adverse effects.

Non-selective H1 receptor antagonists are contraindicated with tranylcypromine.

Concomitant use increases risk of serotonin syndrome. Sertraline is contraindicated in patients taking MAOIs.

Concomitant use of MAOI tranylcypromine with sertraline hydrochloride increases risk of serotonin syndrome.

MAOI interaction may cause serotonin syndrome or opioid toxicity. Do not use or within 14 days of stopping.

Concomitant use increases risk of serotonin syndrome. Trazodone is contraindicated in patients taking MAOIs.

Concomitant use with MAOIs increases risk of serotonin syndrome. Contraindicated with MAOI or within 14 days of stopping MAOI.

Inhibition of MAO prolongs and potentiates dopamine effects, potentially resulting in severe hypertension and cardiac arrhythmia.

Use with caution due to potential for hypotensive effects when combined with tranylcypromine.

CYP2C19 inhibitor that decreases diazepam elimination, potentially increasing adverse reactions.